{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:49:11Z","timestamp":1782121751206,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"DOI":"10.1038\/s41390-026-05217-8","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:08:06Z","timestamp":1782119286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the effect of CFTR modulator therapy on lipid profiles in children"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-1918","authenticated-orcid":false,"given":"Ayy\u00fcce","family":"\u00dcnl\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9224-5237","authenticated-orcid":false,"given":"\u015eule Selin","family":"Akyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7009-4917","authenticated-orcid":false,"given":"Sat\u0131","family":"\u00d6zkan Tabak\u00e7\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9598-5989","authenticated-orcid":false,"given":"I\u015f\u0131l","family":"Bilgi\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-2369","authenticated-orcid":false,"given":"Meltem","family":"K\u00fcrt\u00fcl \u00c7akar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3897-5650","authenticated-orcid":false,"given":"Gamze","family":"Akca Din\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-9545","authenticated-orcid":false,"given":"Hande","family":"Yeti\u015fgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9858-454X","authenticated-orcid":false,"given":"\u00c7elebi","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9804-1200","authenticated-orcid":false,"given":"G\u00f6k\u00e7en Dil\u015fa","family":"Tu\u011fcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0334-6336","authenticated-orcid":false,"given":"Dilber","family":"Ademhan Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2309-7952","authenticated-orcid":false,"given":"Sanem","family":"Ery\u0131lmaz Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-196X","authenticated-orcid":false,"given":"G\u00fczin","family":"Cinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"5217_CR1","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan, B. P. & Freedman, S. D. Cystic fibrosis. Lancet 373, 1891\u20131904 (2009).","journal-title":"Lancet"},{"key":"5217_CR2","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/ppul.26535","volume":"58","author":"G Veit","year":"2023","unstructured":"Veit, G. et al. Patients with cystic fibrosis who could not receive the CFTR modulator treatment: what did they lose in 1 year?. Pediatr. Pulmonol. 58, 2505\u20132512 (2023).","journal-title":"Pediatr. Pulmonol."},{"key":"5217_CR3","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/ppul.26535","volume":"58","author":"S Uytun","year":"2023","unstructured":"Uytun, S. et al. Patients with cystic fibrosis who could not receive the CFTR modulator treatment: what did they lose in 1 year?. Pediatr. Pulmonol. 58, 2505\u20132512 (2023).","journal-title":"Pediatr. Pulmonol."},{"key":"5217_CR4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","volume":"385","author":"ET Zemanick","year":"2021","unstructured":"Zemanick, E. T., Taylor-Cousar, J. L. & Davies, J. C. Pediatric outcomes with elexacaftor\/tezacaftor\/ivacaftor. N. Engl. J. Med. 385, 815\u2013825 (2021).","journal-title":"N. Engl. J. Med."},{"key":"5217_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jcf.2020.06.012","volume":"20","author":"PR Burgel","year":"2021","unstructured":"Burgel, P. R. et al. French Cystic Fibrosis Reference Network study group. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. J. Cyst. Fibros. 20, 220\u2013227 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR6","first-page":"552","volume":"204","author":"DP Nichols","year":"2021","unstructured":"Nichols, D. P., Konstan, M. W. & Chmiel, J. F. Clinical impacts of CFTR modulators in cystic fibrosis. Am. J. Respir. Crit. Care Med. 204, 552\u2013560 (2021).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"5217_CR7","first-page":"263","volume":"72","author":"VA Stallings","year":"2021","unstructured":"Stallings, V. A., Stark, L. J., Robinson, K. A., Feranchak, A. P. & Quinton, H. Clinical practice guidelines on growth and nutrition subcommittee. J. Pediatr. Gastroenterol. Nutr. 72, 263\u2013283 (2021).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"5217_CR8","first-page":"132","volume":"161","author":"DM Green","year":"2022","unstructured":"Green, D. M. et al. Weight gain and metabolic concerns with CFTR modulators in adults. Chest 161, 132\u2013140 (2022).","journal-title":"Chest"},{"key":"5217_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","volume":"24","author":"A Gramegna","year":"2025","unstructured":"Gramegna, A. et al. Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy. J. Cyst. Fibros. 24, 53\u201356 (2025).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR10","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/ppul.27051","volume":"59","author":"HN B\u00fcy\u00fck\u015fahin","year":"2024","unstructured":"B\u00fcy\u00fck\u015fahin, H. N. et al. Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators. Pediatr. Pulmonol. 59, 2499\u20132506 (2024).","journal-title":"Pediatr. Pulmonol."},{"key":"5217_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2025.1659633","volume":"13","author":"AP Ergenekon","year":"2025","unstructured":"Ergenekon, A. P. et al. Comparison of interrupted and continuous modulator therapy in cystic fibrosis: a real-life experience in Turkey. Front. Pediatr. 13, 1659633 (2025).","journal-title":"Front. Pediatr."},{"key":"5217_CR12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","volume":"132","author":"BJ Rosenstein","year":"1998","unstructured":"Rosenstein, B. J. & Cutting, G. R. The diagnosis of cystic fibrosis: a consensus statement. J. Pediatr. 132, 589\u2013595 (1998).","journal-title":"J. Pediatr."},{"key":"5217_CR13","unstructured":"Ebrary, inc. WHO Child Growth Standards Length\/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development, 312 (Ebrary, inc., 2006)."},{"key":"5217_CR14","doi-asserted-by":"publisher","first-page":"2000289","DOI":"10.1183\/13993003.00289-2020","volume":"57","author":"GL Hall","year":"2021","unstructured":"Hall, G. L. et al. Official ERS technical standard: GLI reference values for static lung volumes. Eur. Respir. J. 57, 2000289 (2021).","journal-title":"Eur. Respir. J."},{"key":"5217_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1089-3261(05)70363-9","volume":"2","author":"KD Flora","year":"1998","unstructured":"Flora, K. D. & Benner, K. G. Liver disease in cystic fibrosis. Clin. Liver Dis. 2, 51\u201361 (1998).","journal-title":"Clin. Liver Dis."},{"key":"5217_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499\u2013502 (1972).","journal-title":"Clin. Chem."},{"key":"5217_CR17","unstructured":"American Heart Association Compliance Action Program. Commitment of a lifetime. Patient education materials. Internet: http:\/\/www.americanheart.org\/CAP\/patient\/abh\/levels.html (2001) (accessed 19 March 2002)."},{"key":"5217_CR18","doi-asserted-by":"publisher","first-page":"240045","DOI":"10.1183\/16000617.0045-2024","volume":"33","author":"I Fajac","year":"2024","unstructured":"Fajac, I., Burgel, P. R. & Martin, C. New drugs, new challenges in cystic fibrosis care. Eur. Respir. Rev. 33, 240045 (2024).","journal-title":"Eur. Respir. Rev."},{"key":"5217_CR19","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jcf.2023.07.001","volume":"22","author":"T Yuzyuk","year":"2023","unstructured":"Yuzyuk, T. et al. Improvement of lipid and lipoprotein profiles in children and adolescents with CF on CFTR modulator therapy. J. Cyst. Fibros. 22, 1027\u20131035 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.619442","volume":"12","author":"M Veltman","year":"2021","unstructured":"Veltman, M. et al. CFTR correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in CF bronchial epithelial cells. Front. Physiol. 12, 619442 (2021).","journal-title":"Front. Physiol."},{"key":"5217_CR21","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","volume":"39","author":"A Bonhoure","year":"2020","unstructured":"Bonhoure, A. et al. Overweight, obesity and significant weight gain in adult patients with CF: association with lung function and cardiometabolic risk factors. Clin. Nutr. 39, 2910\u20132916 (2020).","journal-title":"Clin. Nutr."},{"key":"5217_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jcf.2023.10.002","volume":"22","author":"KA Despotes","year":"2023","unstructured":"Despotes, K. A., Ceppe, A. S. & Donaldson, S. H. Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis. J. Cyst. Fibros. 22, 1024\u20131026 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR23","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower, J. K. et al. Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study. J. Cyst. Fibros. 22, 730\u2013737 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/phar.2903","volume":"44","author":"K Lonabaugh","year":"2024","unstructured":"Lonabaugh, K. et al. Real-world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis. Pharmacotherapy 44, 231\u2013240 (2024).","journal-title":"Pharmacotherapy"},{"key":"5217_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","volume":"21","author":"MC Petersen","year":"2022","unstructured":"Petersen, M. C., Begnel, L., Wallendorf, M. & Litvin, M. Effect of elexacaftor-tezacaftor- ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J. Cyst. Fibros. 21, 265\u2013271 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jcf.2022.02.005","volume":"21","author":"D Westh\u00f6lter","year":"2022","unstructured":"Westh\u00f6lter, D. et al. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis. J. Cyst. Fibros. 21, 713\u2013720 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3390\/antiox10030483","volume":"10","author":"O Sommerburg","year":"2021","unstructured":"Sommerburg, O. et al. CFTR modulator therapy with lumacaftor\/ivacaftor alters plasma concentrations of lipid-soluble vitamins A and E in patients with cystic fibrosis. Antioxidants 10, 483 (2021).","journal-title":"Antioxidants"},{"key":"5217_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1130790","volume":"11","author":"M Gaschignard","year":"2023","unstructured":"Gaschignard, M., Beaufils, F., Lussac-Sorton, F., Gallet, P., Clouzeau, H. & Menard, J. Nutritional impact of CFTR modulators in children with cystic fibrosis. Front. Pediatr. 11, 1130790 (2023).","journal-title":"Front. Pediatr."},{"key":"5217_CR29","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1002\/ppul.27272","volume":"59","author":"CM L\u00f3pez C\u00e1rdenes","year":"2024","unstructured":"L\u00f3pez C\u00e1rdenes, C. M. et al. Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis. Pediatr. Pulmonol. 59, 3632\u20133640 (2024).","journal-title":"Pediatr. Pulmonol."},{"key":"5217_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","volume":"9","author":"B Rhodes","year":"2010","unstructured":"Rhodes, B. et al. Prevalence of dyslipidemia in adults with cystic fibrosis. J. Cyst. Fibros. 9, 24\u201328 (2010).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcf.2021.01.011","volume":"20","author":"ET Zemanick","year":"2021","unstructured":"Zemanick, E. T., Taylor-Cousar, J. L. & Davies, J. C. Pediatric use of elexacaftor\/tezacaftor\/ivacaftor: clinical implications. J. Cyst. Fibros. 20, 195\u2013207 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"5217_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00408-025-00802-w","volume":"203","author":"IH Iftikhar","year":"2025","unstructured":"Iftikhar, I. H., Rao, S. T., Nadama, R., Janahi, I. & BaHammam, A. S. Comparative efficacy of CFTR modulators: a network meta-analysis. Lung 203, 49 (2025).","journal-title":"Lung"},{"key":"5217_CR33","doi-asserted-by":"crossref","unstructured":"Caley, L. R. et al. Body mass index and nutritional intake following Elexacaftor\/Tezacaftor\/Ivacaftor modulator therapy in adults with cystic fibrosis. J. Cyst. Fibros. 22, 1002\u20131009 (2023).","DOI":"10.1016\/j.jcf.2023.06.010"},{"key":"5217_CR34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clnesp.2020.10.001","volume":"41","author":"T Havermans","year":"2021","unstructured":"Havermans, T., Colpaert, K. & De Boeck, K. Nutritional and weight gain effects of CFTR modulators. Clin. Nutr. ESPEN 41, 168\u2013174 (2021).","journal-title":"Clin. Nutr. ESPEN"},{"key":"5217_CR35","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","volume":"394","author":"HGM Heijerman","year":"2019","unstructured":"Heijerman, H. G. M. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet 394, 1940\u20131948 (2019).","journal-title":"Lancet"},{"key":"5217_CR36","first-page":"192","volume":"25","author":"K Ridley","year":"2020","unstructured":"Ridley, K. & Condren, M. Elexacaftor-tezacaftor-ivacaftor: the first triple combination cystic fibrosis transmembrane conductance regulator modulating therapy. J. Pediatr. Pharmac. Ther. 25, 192\u2013197 (2020).","journal-title":"J. Pediatr. Pharmac. Ther."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05217-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05217-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05217-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:08:15Z","timestamp":1782119295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-026-05217-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":36,"alternative-id":["5217"],"URL":"https:\/\/doi.org\/10.1038\/s41390-026-05217-8","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ankara Bilkent City Hospital Ethics Committee (Reference number: TABED 1-25-1393). All procedures followed the principles of the Declaration of Helsinki. Written informed consent was obtained from patients and\/or legal guardians prior to CFTR modulator therapy initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}